Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 25;15(2):e095804.
doi: 10.1136/bmjopen-2024-095804.

Protocol for a randomised controlled trial of a weight maintenance intervention to promote fat loss in pregnant individuals with obesity

Affiliations

Protocol for a randomised controlled trial of a weight maintenance intervention to promote fat loss in pregnant individuals with obesity

Leanne M Redman et al. BMJ Open. .

Abstract

Introduction: In pregnancy, people with obesity or excess adiposity are prone to excess gestational weight gain (GWG) and have the highest risks for multiple maternal morbidities. Epidemiological studies suggest that the lowest incidence of adverse maternal and infant outcomes occurs with GWG lower than current recommendations (<5 kg) and with gestational weight maintenance, resulting in fat mass loss, in those with obesity. Data from randomised clinical trials are needed to evaluate the efficacy of a fat mass loss intervention on pregnancy outcomes. The objective of this proof-of-principle randomised controlled trial is to test the effect of a gestational fat mass loss intervention in pregnant individuals with obesity on changes in weight, fat mass and cardiometabolic disease risk factors.

Methods and analysis: In this two-site randomised parallel group, 100 women (30% black; 30% Hispanic) with pre-existing obesity (31.0≤body mass index≤55.0 kg/m2) are randomised to usual care (Provider Directed Group) or usual care plus a fat mass loss intervention with food provision (Weight Maintenance Group). The primary outcomes of the trial (Healthy Mamas/Mamis Saludables) are weight, fat mass (via three-compartment model) and cardiometabolic disease risk factors (ie, blood pressure, lipids, glucose, insulin) from baseline (~13 weeks gestation) to ~35 weeks gestation and at 2 weeks postpartum. Secondary aims evaluate the safety of the fat mass loss intervention during pregnancy and test the hypotheses that compared with usual care, the intervention will have no significant adverse effect on fetal growth, neonatal size, infant body composition and other adverse events. Mediators (eg, eating, activity) and moderators (eg, parity, obesity grade, race/ethnicity) of intervention effects are also examined. Finally, the study will explore the effect of prenatal fat mass loss on reducing the incidence of adverse obstetrical outcomes, including non-elective caesarean delivery, gestational diabetes, hypertension and pre-eclampsia.

Ethics and dissemination: The trial has been approved by the Pennington Biomedical Research Center Institutional Review Board, is monitored by an independent data and safety monitoring board and will be conducted in agreement with the Declaration of Helsinki. All results, positive, negative and inconclusive, will be disseminated at national and/or international scientific meetings and in peer-reviewed scientific journals.

Trial registration number: NCT04731688.

Keywords: NUTRITION & DIETETICS; Obesity; Pregnancy; Pregnant Women; Randomized Controlled Trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Unrelated to this work, SP has a grant from WeightWatchers. All other authors have no competing interest to declare.

Figures

Figure 1
Figure 1. Healthy Mamas/Mamis Saludables clinical trial design. Example weight trajectories for individuals randomised to Usual Care vs Weight Maintenance Groups. GWG, gestational weight gain.
Figure 2
Figure 2. Healthy Mamas/Mamis Saludables multicomponent behavioural intervention.

References

    1. Frey HA, Ashmead R, Farmer A, et al. Association of Prepregnancy Body Mass Index With Risk of Severe Maternal Morbidity and Mortality Among Medicaid Beneficiaries. JAMA Netw Open . 2022;5:e2218986. doi: 10.1001/jamanetworkopen.2022.18986. - DOI - PMC - PubMed
    1. Heslehurst N, Ngongalah L, Bigirumurame T, et al. Association between maternal adiposity measures and adverse maternal outcomes of pregnancy: Systematic review and meta-analysis. Obes Rev. 2022;23:e13449. doi: 10.1111/obr.13449. - DOI - PMC - PubMed
    1. Voerman E, Santos S, Inskip H, et al. Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes. JAMA. 2019;321:1702–15. doi: 10.1001/jama.2019.3820. - DOI - PMC - PubMed
    1. Goldstein RF, Abell SK, Ranasinha S, et al. Association of Gestational Weight Gain With Maternal and Infant Outcomes: A Systematic Review and Meta-analysis. JAMA. 2017;317:2207–25. doi: 10.1001/jama.2017.3635. - DOI - PMC - PubMed
    1. Diab YH, Huang J, Nehme L, et al. Temporal Trend in Maternal Morbidity and Comorbidity. Am J Perinatol. 2024;41:1867–73. doi: 10.1055/s-0044-1782598. - DOI - PubMed

Publication types

Associated data